eflornithine placebo + sulindac

eflornithine placebo + sulindac refers to a specific treatment arm within the Phase III PACES (Preventing Adenomas of the Colon with Eflornithine and Sulindac) clinical trial, also designated as SWOG S0820. This study, conducted by the SWOG Cancer Research Network, evaluates chemoprevention strategies to reduce the recurrence of high-risk adenomas and second primary colorectal cancers in patients previously treated for Stage 0-III colon or rectal cancer. In this particular arm, participants receive active sulindac (150 mg daily) and a placebo matching the eflornithine tablets. Sulindac is a nonsteroidal anti-inflammatory drug (NSAID) that acts as a prodrug; its active sulfide metabolite is a non-selective inhibitor of cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2). By inhibiting these enzymes, sulindac reduces the synthesis of prostaglandins, which are lipid mediators implicated in colorectal carcinogenesis and tumor promotion. The trial aims to determine the efficacy of sulindac monotherapy compared to eflornithine, the combination of both agents, or a double placebo control.

Brand names

Clinoril

Other names

eflornithine placebo + sulindac-SWOG Cancer Research Network-colorectal neoplasmsulindaceflornithine placebo and sulindacS0820 sulindac armS-0820 sulindac armS 0820 sulindac arm